Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

News in Brief

Tweaking Transcription to Stop AML Cell Growth

DOI: 10.1158/2159-8290.CD-NB2015-149 Published December 2015
  • Article
  • Info & Metrics
Loading

A new way to alter gene expression in leukemia cells may offer a fast track to treatment, according to a recent study in Nature. Matthew D. Shair, PhD, and colleagues at Harvard University in Cambridge, MA, show that a natural product derived from sea sponges possesses potent anticancer activity against acute myeloid leukemia (AML) cell lines in vitro and in a mouse model, without apparent toxicity. They found that the compound, cortistatin A (CA), is a highly specific inhibitor of the cyclin-dependent kinases (CDK) 8 and 19, which help to modulate gene expression through DNA regulatory elements known as super-enhancers (SE).

CA “may represent a unique new way we can perturb transcription,” says Christopher Vakoc, MD, PhD, of Cold Spring Harbor Laboratory in New York, who was not involved in the work.

CA is not the first molecule to target transcriptional regulation in cancer cells. Several antitumor drugs in development, including inhibitors of the bromodomain protein BRD4 and CDK7, suppress the activity of SE-associated proteins to cause widespread dampening of transcription.

However, CA appears to work differently. As part of the study, the researchers performed transcriptome analysis and found that CA did not decrease overall transcription, but it upregulated a small number of SE-controlled genes, which was sufficient to suppress leukemia cell growth.

The results suggest that cancers use SEs not only to turn up gene expression, but also to fine-tune expression levels. Shair thinks that AML must be very sensitive to the dosage of some genes. “Like in the story of Goldilocks—it has to be just right,” he says.

“It really suggests that the transcriptional circuitry of cancer cells, and leukemia cells in particular, is quite fragile,” says Ross L. Levine, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, who was not involved in the study. Even small changes can “push cells over the edge.”

Going forward, “It will be very interesting to understand what genotypes of leukemia, and what specific mutational drivers, are associated with response and resistance to the drug,” says Benjamin L. Ebert, MD, PhD, of Brigham and Women's Hospital in Boston, MA, who was also not involved in the study. “They used mainly cell lines to characterize the drug so far. It will be really interesting to understand what the responses look like in primary tumor samples with a wide range of genotypes.”

In the meantime, Shair said his group has synthesized new, structurally simpler compounds related to CA that can be given orally, can be made more easily on a large scale than CA, and work in animal models of AML. They are talking with potential industry partners about moving these new lead compounds into clinical trials.

The need for new treatments for AML is pressing, notes Levine. “The treatment for AML has not changed for more than 30 years, so to have this novel drug against a novel target with potential efficacy is really exciting,” he says.

  • ©2015 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 5 (12)
December 2015
Volume 5, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Tweaking Transcription to Stop AML Cell Growth
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Tweaking Transcription to Stop AML Cell Growth
Cancer Discov December 1 2015 (5) (12) OF1; DOI: 10.1158/2159-8290.CD-NB2015-149

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Tweaking Transcription to Stop AML Cell Growth
Cancer Discov December 1 2015 (5) (12) OF1; DOI: 10.1158/2159-8290.CD-NB2015-149
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • By The Numbers: Novel Drugs Approved by the FDA, 2011-2020
  • The National Cancer Act at 50
  • Congress Approves Increase in Cancer Funding
Show more News in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement